Dopamine agonists and valvular heart disease [2]

New England Journal of Medicine

Volumn 356, Issue 16, 2007, Pages 1676-1680

  Stephens, Jeffrey W ^a   Price, David E ^a   Ionescu, Adrian ^a  

^a MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; ERGOLINE DERIVATIVE;

DISEASE SEVERITY; DRUG RESPONSE; ECHOCARDIOGRAPHY; HUMAN; HYPERPROLACTINEMIA; LETTER; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; MALE; MIDDLE AGED; NOTE; PARKINSON DISEASE; DRUG EFFECT; HEART VENTRICLE REMODELING;

DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; ERGOLINES; HYPERPROLACTINEMIA; VENTRICULAR REMODELING;

EID: 34247255452     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070227     Document Type: Letter

References (2)

1. Schade R, Anderson F, Suissa S, Haverkamp W, Garde E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
2. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.